Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress

We have previously identified peroxiredoxin-3 as a cell-surface protein that is androgen regulated in the LNCaP prostate cancer cell line

H C Whitaker; D Patel; W J Howat; A Y Warren; J D Kay; T Sangan; J C Marioni; J Mitchell; S Aldridge; H J Luxton; C Massie; A G Lynch; D E Neal


Scholarcy highlights

  • Experimental design: PRDX-3 expression was examined in tissue from 32 patients using immunohistochemistry
  • PRDX-3 is upregulated in a number of endocrine-regulated tumours; in particular in prostate cancer and prostatic intraepithelial neoplasia
  • The majority of PRDX-3 is localised to the mitochondria, we have confirmed that PRDX-3 at the cell membrane is androgen regulated
  • Our results suggest that PRDX-3 has an essential role in regulating oxidation-induced apoptosis in antiandrogenresistant cells
  • The PRDX proteins catalyse the reduction of molecules that cause oxidative stress such as reactive oxygen species, for example, peroxides that are essential metabolic intermediates and regulators of growth factor signalling but are often produced as a result of cellular stress
  • Using a matched tumour and normal tissue microarrays containing tissue cores from a variety of organs, we investigated the expression of PRDX-3 using immunofluorescent staining
  • Catalysis of reactive oxygen species leads to oxidised SO2 and SO3 forms of the PRDX proteins which can be reduced, and reactivated, via a thioredoxin and BRITISH JOURNAL OF CANCER

Need more features? Save interactive summary cards to your Scholarcy Library.